莱茵生物
(002166)
| 流通市值：63.59亿 | | | 总市值：63.85亿 |
| 流通股本：7.39亿 | | | 总股本：7.42亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 446,871,087.43 | 2,043,836,317.7 | 1,272,155,817.35 | 836,964,658.02 |
| 营业收入 | 446,871,087.43 | 2,043,836,317.7 | 1,272,155,817.35 | 836,964,658.02 |
| 二、营业总成本 | 401,670,515.61 | 1,858,906,809.19 | 1,186,425,574.15 | 784,217,763.94 |
| 营业成本 | 340,886,015.51 | 1,517,520,305.05 | 954,100,869.39 | 639,724,970.48 |
| 税金及附加 | 2,160,017.18 | 14,435,093.18 | 9,545,587.79 | 5,212,071.79 |
| 销售费用 | 17,407,178 | 75,796,528.12 | 49,062,312.72 | 32,472,162.32 |
| 管理费用 | 20,818,558.4 | 148,962,388.27 | 95,993,427.82 | 62,143,099.21 |
| 研发费用 | 6,719,909.37 | 58,351,557.36 | 50,415,865.89 | 26,217,118.08 |
| 财务费用 | 13,678,837.15 | 43,840,937.21 | 27,307,510.54 | 18,448,342.06 |
| 其中:利息费用 | 9,246,050.64 | 43,004,805.42 | 29,656,395.73 | 20,519,180.34 |
| 其中:利息收入 | 688,913.85 | 2,887,497.45 | 2,341,351.29 | 1,237,839.71 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -292,617.7 | 4,246,764.89 | 4,376,919.11 | -207,129.89 |
| 加:投资收益 | 52,733.38 | 4,600,454.64 | 4,606,188.91 | 74,624.01 |
| 资产处置收益 | - | -129,684.76 | -109,497.53 | -109,497.53 |
| 资产减值损失(新) | - | 1,344,480.6 | -568,553.16 | -422,147.6 |
| 信用减值损失(新) | 2,844,678.45 | -13,576,369.23 | 1,427,281.7 | 1,590,905.19 |
| 其他收益 | 3,806,091.25 | 23,551,672.98 | 11,119,495.69 | 9,615,476.57 |
| 四、营业利润 | 51,611,457.2 | 204,966,827.63 | 106,582,077.92 | 63,289,124.83 |
| 加:营业外收入 | 33,661.55 | 26,991.47 | 25,373.43 | 22,342.68 |
| 减:营业外支出 | 49,309.69 | 4,293,094.03 | 1,677,788.31 | 945,230.92 |
| 五、利润总额 | 51,595,809.06 | 200,700,725.07 | 104,929,663.04 | 62,366,236.59 |
| 减:所得税费用 | 8,955,424.47 | 47,817,138.8 | 25,737,819.48 | 18,693,815.48 |
| 六、净利润 | 42,640,384.59 | 152,883,586.27 | 79,191,843.56 | 43,672,421.11 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 42,640,384.59 | 152,883,586.27 | 79,191,843.56 | 43,672,421.11 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 42,516,534.18 | 143,124,616.54 | 70,395,252.98 | 38,109,978.8 |
| 少数股东损益 | 123,850.41 | 9,758,969.73 | 8,796,590.58 | 5,562,442.31 |
| 扣除非经常损益后的净利润 | 40,328,168.97 | 126,649,063.85 | 61,452,646.39 | 33,693,373.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.19 | 0.1 | 0.05 |
| (二)稀释每股收益 | 0.06 | 0.19 | 0.1 | 0.05 |
| 八、其他综合收益 | -10,543,840.78 | -6,907,607.08 | -1,069,684.73 | 2,319,069.71 |
| 归属于母公司股东的其他综合收益 | -10,543,840.78 | -6,907,607.08 | -1,069,684.73 | 2,319,069.71 |
| 九、综合收益总额 | 32,096,543.81 | 145,975,979.19 | 78,122,158.83 | 45,991,490.82 |
| 归属于母公司股东的综合收益总额 | 31,972,693.4 | 136,217,009.46 | 69,325,568.25 | 40,429,048.51 |
| 归属于少数股东的综合收益总额 | 123,850.41 | 9,758,969.73 | 8,796,590.58 | 5,562,442.31 |
| 公告日期 | 2026-04-30 | 2026-03-31 | 2025-10-28 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |